

FINALISTS 2022

Best Contract Research Organization – Full-Service Providers

The Scrip Awards for Best Contract Research Organization acknowledge the critical role that CROs play in drug development. This Award is for those companies which provide the full range of services to their clients.

Altasciences

Altasciences has evolved from a single-site CRO focused solely on generic drug development to an eight-site company that also supports novel drug development, from lead candidate selection to clinical proof of concept, and beyond. It integrates its solutions and teams to mitigate risk and save sponsors up to 40% in time and costs on their programs.

CMIC

The first clinical CRO in Japan, today CMIC is involved in close to 80% of new drug development and filing in the country. Over the last 30 years, CMIC has developed a unique “Pharmaceutical Value Creator” business model based on its abundant experience and knowledge as a CRO pioneer, and the company now offers comprehensive services that encompass the entire pharma value-chain.

ICON

With the integration of PRA Health Sciences progressing smoothly and effectively, ICON is capitalizing on the scale, technology and data analytics capabilities that the acquisition delivers, offering the most comprehensive suite of integrated clinical development services in the industry. It has a unique operational model and experience gained in a wide range of studies, including the first fully decentralized clinical trial approved by the FDA.

IQVIA

IQVIA's Connected Intelligence brings together its portfolio of capabilities, data, advanced analytics and data science, innovative technologies and trial expertise to create intelligent connections that have allowed the company to broaden its Decentralized Clinical Trial platform, create commercial value with the launch of the IQVIA Innovation Hub and streamline data collection with the launch of IQVIA's Real-Time Data Cleaning.

Novotech

About 50% of Novotech's revenue comes from clients in Asia-Pacific, the fastest-growing region for clinical trials globally. The recent acquisition of a large US CRO has enabled Novotech to provide US-based expertise and infrastructure for US and EU clients wanting trials in Asia-Pacific and the US, and for Asia-Pacific clients wanting US clinical programs.

Parexel

Over the past year, Parexel has accelerated the next phase of its growth through the transition to its new private equity ownership, with a shared commitment to a patients-first focus and innovation in key areas, including DCTs and RWE, Asia/Pacific and biotech. Parexel has formed innovative collaborations in rare diseases, oncology and has earned recognition for the advancement of women.

SCRIP AWARDS 2022

30 NOVEMBER 2022 · ROYAL LANCASTER, LONDON

PPD, Part of Thermo Fisher Scientific

Acquired by Thermo Fisher in December 2021, PPD offers a comprehensive suite of world-class products and services across the drug development spectrum. Helping customers accelerate promising medicines from early development through regulatory approval and market access, the business covers all clinical phases, comprehensive laboratory services, and peri- and post-approval services, as well as offering a purpose-built delivery model for biotech customers.

Syneos Health

Over the past year, Syneos Health made significant progress expanding its business and further developing innovative integrated offerings, enabled by data and technology to position itself for long-term success. The company's innovative trial design expertise creates new ways to accelerate patient access, improve retention and increase diversity to achieve its purpose of shortening the distance from lab to life.

Winners are announced at the Awards ceremony and dinner on Wednesday 30th November at the Royal Lancaster Hotel, London.